Literature DB >> 8796879

Muscle-based gene therapy: realistic possibilities for the future.

E C Svensson1, S K Tripathy, J M Leiden.   

Abstract

The past five years have witnessed tremendous growth in the field of gene therapy, with pre-clinical and clinical gene therapy trials for diseases as diverse as cancer, AIDS and atherosclerosis. These studies have utilized many different vectors and target organs in order to achieve therapeutic effects. In this review, we examine the rationale for using skeletal muscle as a target tissue for gene therapy, discuss the wide array of vectors that have been used for muscle-based gene therapy, summarize the disease-targets that have been approached using these techniques, and discuss some of the obstacles that remain to be overcome en route to successful muscle-based human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8796879     DOI: 10.1016/1357-4310(96)88792-2

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  5 in total

1.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Genetic vaccines: strategies for optimization.

Authors:  G Gregoriadis
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 3.  Gene therapy for dyslipidemia: clinical prospects.

Authors:  D J Rader; U J Tietge
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.113

4.  In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery.

Authors:  G A Brazeau; S Attia; S Poxon; J A Hughes
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

5.  The role of cell type in bone healing mediated by ex vivo gene therapy.

Authors:  Tim Rose; Hairong Peng; Hsain-Chung Shen; Arvydas Usas; Ryosuke Kuroda; Helmut Lill; Freddie H Fu; Johnny Huard
Journal:  Langenbecks Arch Surg       Date:  2003-10-08       Impact factor: 3.445

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.